<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584960</url>
  </required_header>
  <id_info>
    <org_study_id>H-D-2008-015</org_study_id>
    <nct_id>NCT01584960</nct_id>
  </id_info>
  <brief_title>The Effect of Endurance Training in Patients With Prostate Cancer</brief_title>
  <official_title>The Effect of Endurance Training on PSA Doubling Time, Body Composition, Insulin Sensitivity and Inflammation in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inge Holm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate the effect of endurance on PSA doubling time
      in prostate cancer patients with an elevation in PSA following radical prostatectomy for
      localized cancer. Furthermore, underlying mechanisms such as reduction in inflammatory
      markers and improvement in insulin sensitivity and body composition are investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA doubling time</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity, body composition and inflammation status</measure>
    <time_frame>0 months, 6 months and 24 months of training</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Insulin Sensitivity</condition>
  <condition>Body Composition, Beneficial</condition>
  <arm_group>
    <arm_group_label>Prostate cancer, endurance training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prostate cancer patients doing 2 years of home-based endurance training Cross over design with a control group with no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>endurance training</intervention_name>
    <description>2 years of home-based endurance training</description>
    <arm_group_label>Prostate cancer, endurance training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate cancer patients with an increase in PSA following radical prostatectomy

        Exclusion Criteria:

          -  severe cardiovascular disease

          -  severe arthritis

          -  severe neuropathy

          -  severe hypertension

          -  therapy with antidiabetic agents

          -  other treatment for prostate cancer than radical prostatectomy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente K Pedersen</last_name>
    <role>Study Director</role>
    <affiliation>Centre of Inflammation and Metabolism, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre of Inflammation and Metabolism, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>November 29, 2013</last_update_submitted>
  <last_update_submitted_qc>November 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Inge Holm</investigator_full_name>
    <investigator_title>Administrator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

